EsoCap has been selected as a finalist to present at the RESI Europe 2020 Innovation Challenge from 200+ companies.
The RESI (Redefining Early Stage Investment) conference series was created to bring together startups in the biotech, medtech and digital health areas with early-stage investors. The goal is to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. The RESI conference is held annually in the USA, Europe and Asia.
“We are very excited to present at the RESI Europe 2020 conference in Paris”, said Isabelle Racamier, EsoCap AG CEO. “This is a great validation of the innovative nature of our technology and business strategy.” The EsoCap unique topical application technology may be beneficial in at least six indications affecting 370 million patients, including gastroenterology, oncology and orphan diseases. “EsoCap smart application technology is a paradigm shift for the effective and safe treatment of esophageal diseases” said Dr. Peter Stangier, EsoCap AG Director Strategic Planning.
